Drug interactions
Lutetium lu-177 oxodotreotide + Octreotide
Severity: Major
Lutetium lu-177 oxodotreotide and Octreotide: major interaction.
Last updated Sources: US FDA label
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Octreotide binds the same somatostatin receptors that lutetium Lu-177 oxodotreotide targets, so it can compete for tumor uptake. This may lower radioligand delivery and reduce the efficacy of therapy.
What this interaction means in plain words
Lutetium lu-177 oxodotreotide and Octreotide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Lutetium lu-177 oxodotreotide belongs to Miscellaneous; Octreotide belongs to Endocrine.
Why it happens
Competitive binding at somatostatin receptors reduces tumor uptake of the radiolabeled peptide.
What to do
Stop long-acting octreotide at least 4 weeks before each dose and short-acting octreotide at least 24 hours before. Short-acting octreotide may be given for symptom control between doses, subject to these timing restrictions.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lutetium lu-177 oxodotreotide and Octreotide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
References
Other interactions of Octreotide
Frequently asked questions
Can I take Lutetium lu-177 oxodotreotide with Octreotide?
MediHelp rates the interaction as major. Lutetium lu-177 oxodotreotide and Octreotide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Octreotide binds the same somatostatin receptors that lutetium Lu-177 oxodotreotide targets, so it can compete for tumor uptake. This may lower radioligand delivery and reduce the efficacy of therapy.
How serious is the interaction between Lutetium lu-177 oxodotreotide and Octreotide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Stop long-acting octreotide at least 4 weeks before each dose and short-acting octreotide at least 24 hours before. Short-acting octreotide may be given for symptom control between doses, subject to these timing restrictions.
What other medicines interact with Octreotide?
MediHelp also lists interactions of Octreotide with, for example, Adagrasib, Amisulpride, Arsenic trioxide. The full list is on the Octreotide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
